New York Senate Bill S08656

New York 2025-2026 Regular Session

• Introduced: 1/7/26
• Refer: 1/7/26
• Report Pass: 1/20/26
• Engrossed: 1/27/26
• Refer: 1/27/26

Caption

Provides that mifepristone or misoprostol may be dispensed without the name and address of the dispenser and patient included on the prescription label.

Summary

S08656 amends the Education Law to change how prescriptions for mifepristone and misoprostol are labeled when dispensed in New York. Under the bill, these medications may be dispensed without the dispenser’s name and address and, in the case of the prescriber-requested provision, without the owner of the dispensing establishment, the prescriber’s name, and the patient’s name and address appearing on the prescription label. Instead, the label must include a prescription number or another identifier that can be used to track the prescription. The bill also requires pharmacists or other dispensers to maintain a log containing the prescription number and the identifying information that is omitted from the label, and to keep those records for at least five years. It expressly preserves the ability of law enforcement to investigate criminal activity, but limits disclosure to records strictly necessary for that investigation. The act takes effect immediately.

Impact

This bill narrows the labeling requirements in sections 6807 and 6810 of the Education Law for mifepristone and misoprostol, creating a privacy-focused exception for these medications. It affects pharmacists, prescribers, dispensing establishments, patients, and records custodians by allowing identifying information to be withheld from the prescription label while still requiring internal recordkeeping and retention. The measure does not eliminate traceability; it shifts identifying details from the label to confidential logs available only as needed for criminal investigations.

Sentiment

The voting history suggests the bill had meaningful but not unanimous support. It passed the Senate Higher Education Committee 9-2, the Senate Rules Committee 13-6, and the Senate floor 37-21, indicating a majority in favor but with a substantial minority opposed. The available record shows no committee transcript, so the main evidence of sentiment comes from the votes themselves, which point to a generally supportive but divided response.

Contention

The likely point of contention is the balance between patient privacy and transparency in the dispensing of abortion-related medications. Supporters appear to favor reducing the amount of personal and provider-identifying information printed on labels, likely to protect confidentiality and reduce risk of stigma or harassment. Opponents likely object to limiting label information or may be concerned about reduced visibility for oversight, though the bill preserves internal logs and law-enforcement access for criminal investigations. The split votes indicate that privacy protections for mifepristone and misoprostol were the central issue.